Bolt Biotherapeutics (BOLT) Q3 2025 earnings summary

Executive summary

• Focused on developing novel immunotherapies for cancer, leveraging proprietary Boltbody ISAC platform and myeloid biology expertise, with emphasis on BDC-4182 and BDC-3042.

• Pipeline prioritization led to discontinuation of trastuzumab imbotolimod (BDC-1001) and focus on BDC-3042 and BDC-4182.

• Workforce reduced by ~50% in May 2024 and again by ~50% in October 2025 to preserve cash.

• No product sales; revenue derived solely from collaborations with Toray, Genmab, and Innovent.

• Presented preclinical data at SITC showing BDC-4182's strong tumor-dependent immune response and complete tumor regression in models.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $38.8M as of September 30, 2025, expected to fund operations into 2027.

• Collaboration revenue was $2.2M for Q3 2025 (up $1.1M YoY) and $5.2M for nine months (down $2.5M YoY).

• Net loss was $7.1M for Q3 2025 (improved by $8.0M YoY) and $26.7M for nine months (improved by $20.4M YoY).

• R&D expenses decreased to $6.5M for Q3 2025 (down $7.3M YoY) and $23.5M for nine months (down $22.2M YoY), mainly due to lower salary and clinical expenses after discontinuing BDC-1001.

• G&A expenses were $3.3M for Q3 2025 (down $0.5M YoY) and $10.7M for nine months (down $3.8M YoY), reflecting lower salary costs post-restructuring.

Outlook and guidance

• Cash runway projected into 2027, but substantial doubt exists about ability to continue as a going concern within one year due to uncertainty in collaboration income.

• Initial clinical data for BDC-4182 Phase 1 study anticipated in Q3 2026.

• Additional capital will be required to advance programs; options include partnering, equity, or other financing.

• Ongoing focus on cost reduction and portfolio prioritization.

• Actively seeking partners for BDC-3042 and CEA ISAC programs.